Scientists at Harvard Medical School have developed a nasal spray to treat Alzheimer’s disease. In this respect reports “Reedus.” It was announced that the drug reduced brain inflammation and improved cognitive function, regardless of the amount of beta-amyloid plaques that lead to neuron loss.
The researchers found that intranasal administration of anti-CD3 increased the number of regulatory T cells in the periphery, which then infiltrated the brain, reducing neuroinflammation. During the experiment, it was emphasized that the drug improved cognitive abilities in both male and female mice, as well as short-term memory in females.
The scientists also tested whether the active ingredients in the spray affected gene expression in the cerebral cortex and hippocampus, the main targets of all types of dementia. The result was positive. Researchers now plan to move on to human trials.
Scientists from Stanford University previously discovered A mutation in the PLCG2 gene that may reduce the risk of Alzheimer’s disease. The authors of the discovery believe that it affects the functioning of immune cells in the brain, proving that Alzheimer’s disease is an immune disease.
Previous scientists named the producthelping fight dementia.